Illumina Stakes A Claim In NIPT Market With $450-Million Acquisition Of Verinata

Gene-sequencing company Illumina has signed a definitive agreement to acquire Verinata Health for up to $450 million, staking its claim in the fast-growing, noninvasive prenatal genetic-testing market.